These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35210015)

  • 1. AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
    Altayar O; Shah R; Chang CY; Falck-Ytter Y; Muir AJ
    Gastroenterology; 2022 Mar; 162(3):937-951. PubMed ID: 35210015
    [No Abstract]   [Full Text] [Related]  

  • 2. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
    Su GL; Altayar O; O'Shea R; Shah R; Estfan B; Wenzell C; Sultan S; Falck-Ytter Y
    Gastroenterology; 2022 Mar; 162(3):920-934. PubMed ID: 35210014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
    Chen SC; Chao Y; Yang MH
    Am J Gastroenterol; 2017 Apr; 112(4):659-660. PubMed ID: 28381841
    [No Abstract]   [Full Text] [Related]  

  • 5. Review article: systemic treatment of hepatocellular carcinoma.
    Pinter M; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west.
    Lu J; Zhang XP; Zhong BY; Lau WY; Madoff DC; Davidson JC; Qi X; Cheng SQ; Teng GJ
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):721-730. PubMed ID: 31387735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma: sorafenib before liver transplantation?
    Braillon A
    Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
    [No Abstract]   [Full Text] [Related]  

  • 8. Pursuing efficacious systemic therapy for hepatocellular carcinoma.
    Cheng AL
    Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):95-96. PubMed ID: 33408363
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatocellular carcinoma: Current situation and challenge.
    Li Z; Zhu JY
    Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):303-304. PubMed ID: 31253577
    [No Abstract]   [Full Text] [Related]  

  • 10. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
    Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
    Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
    Walter H; Thomas AL
    Br J Cancer; 2013 Jun; 108(12):2417-8. PubMed ID: 23801031
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
    Chen J; Wang J; Xie F
    Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.
    Tsilimigras DI; Moris D
    J BUON; 2021; 26(2):637. PubMed ID: 34077021
    [No Abstract]   [Full Text] [Related]  

  • 14. Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Mimura T; Minami A; Momose K; Hirano H; Tanaka M; Ueda Y; Tai K; Yasuhara Y; Nakagawa D; Yamamoto A; Kido M; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2024 Jul; 44(7):3097-3103. PubMed ID: 38925835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
    Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
    J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
    da Fonseca LG; Reig M; Bruix J
    Clin Liver Dis; 2020 Nov; 24(4):719-737. PubMed ID: 33012455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
    Rowe IA
    Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies.
    Raghav A; Jeong GB
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
    Hagymási K; Tulassay Z
    Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.